Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "Ltd."

577 News Found

GSK completes acquisition of Aiolos Bio
News | February 19, 2024

GSK completes acquisition of Aiolos Bio

The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody


Internal restructuring of foreign subsidiaries at Bliss GVS Pharma
News | February 17, 2024

Internal restructuring of foreign subsidiaries at Bliss GVS Pharma

The restructuring aims to create synergies across the business and strengthen capital structure


YS Biopharma appoints new Directors
People | February 17, 2024

YS Biopharma appoints new Directors

The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024


Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
News | February 16, 2024

Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr

he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business


Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
News | February 16, 2024

Marksans Q3 FY24 revenue up 22% at Rs 586 Cr

Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%


Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr
Diagnostic Center | February 13, 2024

Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr

These re-agent and diagnostic test kits come with 99.7% accuracy


Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur
News | February 10, 2024

Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur

The 200 bedded hospital owned & operated by Alexis


Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
News | February 09, 2024

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore


MIRA Pharmaceuticals announces collaboration with Pharmaseed
News | February 08, 2024

MIRA Pharmaceuticals announces collaboration with Pharmaseed

Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024